

New Generation Pneumococcal 15-valent Conjugate Vaccine

Prevents serotype 3 accurately & builds
an immune barrier



Elicits 60%
higher
immunogenicity



Generates 8
times or more
antibodies



Protective efficacy
can last for more
than 10 years




Approved
by the US
FDA and EU



*This content is provided by Merck Sharp & Dohme Ltd.


The Deadly Killer "Pneumonia"

Pneumonia is the **2nd** leading cause of death after cancer




Fatal cases have increased by more than **2 times** compared to 20 years ago


Pneumococcus is a common bacterium that causes bacterial pneumonia, and can be transmitted through coughing or sneezing.



Symptoms



Severe conditions



*This content is provided by Merck Sharp & Dohme Ltd.

The Most Threatening Pneumococcus

“Serotype 3”

There are over 100 serotypes of pneumococcus, among which serotype 3 poses the greatest threat! Regardless of age, most severe and hospitalized cases of pneumococcal infections are due to serotype 3.



In Hong Kong, nearly half of the invasive pneumococcal disease cases are caused by serotype 3, with

a death rate of up to 30% - 47%.

As serotype 3 is good at evading attacks from the immune system, it is estimated that eight times or more antibodies are required to confer protection against it.



Eight times or more antibodies



High-Risk Groups for Pneumococcal Infections

1. Children's killer - under 5 years old

Pneumococcus is the most common cause of bacterial pneumonia in children worldwide. According to 2019 statistics, about 740,000 children under 5 years old died of pneumonia globally; over **70%** of invasive pneumococcal disease cases in Hong Kong children are caused by serotype 3. The incidence rate of invasive pneumococcal disease in asthmatic children is **four times** higher than that in general children.



2. The elderly's enemy - 50 years old or above

About 95% of pneumonia deaths are patients aged 65 or above.




Other high-risk groups



People with lung disease



People with cardiovascular disease



People with diabetes



Binge drinkers



Smokers




People with weakened immune systems (especially HIV carriers)

*This content is provided by Merck Sharp & Dohme Ltd.

New Generation Pneumococcal 15-valent Conjugate Vaccine

Focuses on combating serotype 3




Currently, the new generation pneumococcal 15-valent conjugate vaccine has been approved for use by the US FDA and the EU, and is widely used in European and American countries such as the US, the UK and Canada, as well as Australia.



Suitable for:

Infants and individuals aged 6 weeks or above can receive the vaccine to prevent pneumonia and invasive diseases such as meningitis and sepsis caused by 15 serotypes of pneumococcus.

1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F, 33F



Vaccination is recognized as a key preventive measure against invasive pneumococcal disease, and the 15-valent pneumococcal conjugate vaccine (PCV15) is currently the most effective vaccine available for protecting infants and young children against pneumococcal pneumonia.

To provide lifelong protection, PCV15 requires 1 to 4 doses depending on age:

- Aged 6 weeks - 7 months: 3 doses at 2, 4, and 12 months old
- Aged 7-11 months: 3 doses, with 2nd dose administered at least 1 month after 1st dose, and 3rd dose administered at 12 months old or at least 2 months after 2nd dose
- Aged 12-23 months: 2 doses, with 2nd dose administered at least 2 months after 1st dose
- Aged 2 years or older: Only 1 dose

Administration

- Intramuscular injection, recommended site is the deltoid muscle in the arm
- Can be administered simultaneously with inactivated influenza vaccine

Common side effects

In general, the following side effects are mild and temporary: Pain, swelling, and redness at the injection site; fatigue; muscle pain; headache; joint pain

*Starting from July 2019, the Hong Kong Department of Health has reduced the free PCV13 doses for infants born in 2019 and after from 4 to 3, eliminating 3rd dose at 6 months old. Parents may choose to give an extra PCV15 dose at 6 months old for additional protection.

*This content is provided by Merck Sharp & Dohme Ltd.